The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2015 | A review of the treatment evolution in relapsed/refractory multiple myeloma
Paul Richardson
• 12 Jun 2015
Paul Richardson, MD, of Dana-Farber Cancer Institute, Boston, MA, discusses his highlights of the 20th Congress of the European Hematology Association (EHA). A substantial number of new agents, including monoclonal antibodies, and emerging drug classes in clinical development have shown promising activity for the treatment of multiple myeloma.
